Central Pressure and Biomarker Responses to Renin Inhibition with Hydrochlorothiazide and Ramipril in Obese Hypertensives: The ATTAIN Study | Zendy

Adam WhaleyConnell | Zendy; Das Purkayastha | Zendy; Anthony Yadao | Zendy; James R. Sowers | Zendy

Open Access

Central Pressure and Biomarker Responses to Renin Inhibition with Hydrochlorothiazide and Ramipril in Obese Hypertensives: The ATTAIN Study

Author(s) -

Adam WhaleyConnell,

Das Purkayastha,

Anthony Yadao,

James R. Sowers

Publication year - 2011

Publication title -

cardiorenal medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.661

H-Index - 21

eISSN - 1664-3828

pISSN - 1664-5502

DOI - 10.1159/000322864

Subject(s) - ramipril , aliskiren , hydrochlorothiazide , medicine , endocrinology , blood pressure , plasma renin activity , urology , ambulatory blood pressure , ace inhibitor , renin–angiotensin system , angiotensin converting enzyme

In obese, hypertensive subjects, the renin-angiotensin system (RAS) is enhanced and natriuresis impaired, suggesting a role for combination RAS blockade with diuretics. Data suggest that renin inhibition may attenuate diuretic-induced RAS activation and oxidative stress.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research